Leifeng.com news, AI pharmaceutical company MindRank recently announced the completion of the milestone of cooperation with Antengene (6996.HK).
In a tumor dual-target small molecule drug pipeline, Deruizhi Pharmaceutical delivered a total of four AI-assisted design new framework compounds (respectively belonging to four different types of new frameworks).
Through third-party synthesis, Antengene conducted experimental verification on the strict enzyme and cellular levels of the two targets, and found that one of the compounds met the lead compound standard and reached the cooperation milestone agreed upon by the two parties.
It is reported that the lead compound has a novel molecular framework, and the IC50 for dual targets is at or below 50 nM at the level of enzymatic activity, and at the level of cells specifically expressed by one target, the activity is similar to that of the clinical candidate drug.
How to achieve high on-target activity on dual-target small molecules and good selectivity on other targets has always been one of the difficult problems in the industry.
Derui Medicine generates molecules through its self-developed industrial-grade AI drug design platform Molecule Pro, and finally selects four virtual compounds to be synthesized, verified and delivered by the partner.
Officially operating in early 2021, Derui Medicine is an AI-driven new innovative drug research and development company that has completed Series A financing of tens of millions of dollars.
The company’s core team comes from domestic and foreign top pharmaceutical companies and international top AI pharmaceutical companies. The scientific research is led by the vice president of Cambridge University, and some team members have won the world AI competition champion and the world genetic engineering competition gold medal. Its AI pharmaceutical solution has been rated as “one of the 11 most important breakthrough achievements in AI drug research and development in the world in 2018-2020” by Deep Pharma Intelligence.
In addition to cooperating with pharmaceutical companies, Derui also has its own research pipeline. The first self-developed AI-assisted design GPCR target drug pipeline will enter the IND-Enabling Studies stage within 8 months, and is expected to enter the first clinical study in 2023.
In addition, Deruizhi Pharmaceutical also successfully delivered AI-assisted design of allosteric inhibitor PCC molecules to listed pharmaceutical companies in September 2021.
Antengene is a biopharmaceutical company focusing on global development, specializing in oncology and other life-threatening diseases.
At present, Antengene has 13 products under development, of which 5 products have Asia-Pacific rights including the Greater China market, and 8 products have global rights. In multiple Asia-Pacific markets, Antengene has obtained 15 clinical approvals (INDs) and submitted 6 new drug applications (NDAs), of which the NDA in South Korea has been given priority approval. Leifeng Network Leifeng Network
This article is reprinted from: https://www.leiphone.com/category/healthai/5u7ya2DPnzcqDpyF.html
This site is for inclusion only, and the copyright belongs to the original author.